Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.

Item

http://www.wikidata.org/entity/Q40916483

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Susceptibility of Clostridium ...... o SMT19969 and 11 Comparators.

@en

Susceptibility of Clostridium ...... o SMT19969 and 11 Comparators.

@en-gb

type

Item

label

Susceptibility of Clostridium ...... o SMT19969 and 11 Comparators.

@en

Susceptibility of Clostridium ...... o SMT19969 and 11 Comparators.

@en-gb

prefLabel

Susceptibility of Clostridium ...... o SMT19969 and 11 Comparators.

@en

Susceptibility of Clostridium ...... o SMT19969 and 11 Comparators.

@en-gb

P1154

2-s2.0-84957927118

http://www.w3.org/2001/XMLSchema#string

P1433

Antimicrobial Agents and Chemotherapy

P1476

Susceptibility of Clostridium ...... o SMT19969 and 11 Comparators.

@en

P2093

Jonathan Vernon

http://www.w3.org/2001/XMLSchema#string

P2860

Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea.

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich.

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection.

Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes.

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile

Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfr

P304

689-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02000-15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jane Freeman

Mark H. Wilcox

Richard J Vickers

P5530

4767219

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044780157

http://www.w3.org/2001/XMLSchema#string

P6366

2122773956

http://www.w3.org/2001/XMLSchema#string

P698

26552981

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

4704187

http://www.w3.org/2001/XMLSchema#string

P953

92582/